Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical company developing neuroscience programs, specifically Ketamir-2 (an oral ketamine analog for neuropathic pain) and MIRA-55 (a non-psychoactive marijuana analog for anxiety and cognitive decline). The company is also pursuing a strategic merger with SKNY Pharmaceuticals, Inc. to acquire SKNY-1, a candidate for weight loss and smoking cessation. This report covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,537,712) | $(3,321,491) |
| Loss Per Share (Basic/Diluted) | $(0.09) | $(0.19) |
| Cash and Cash Equivalents | $730,475 (as of June 30, 2025) | N/A |
| Total Assets | $868,318 | N/A |
| Total Liabilities | $298,459 | N/A |
| Stockholders' Equity | $569,859 | N/A |
| Operating Cash Flow | N/A | $(2,429,678) used |
| Financing Cash Flow | N/A | $327,222 provided |
Expense Breakdown (Six Months 2025):
- General and Administrative (G&A): $2,540,699
- Research and Development (R&D): $810,601
- Stock-Based Compensation: $1,364,378 (included in G&A and R&D)
Material Changes vs. Prior Period
- Liquidity Decline: Cash balances decreased from $2.83 million at December 31, 2024, to $0.73 million at June 30, 2025, a reduction of approximately $2.1 million.
- Net Loss Improvement: The net loss for the six months ended June 30, 2025 ($3.32 million) was slightly lower than the prior year period ($3.41 million).
- R&D Efficiency: R&D expenses decreased by approximately 41% year-over-year for the six-month period ($0.81 million vs. $1.38 million), primarily due to reduced costs for MIRA-55 development.
- G&A Increase: G&A expenses increased by approximately 20% year-over-year for the six-month period ($2.54 million vs. $2.12 million), driven by higher stock-based compensation.
- Equity Position: Stockholders' equity declined to $0.57 million, raising concerns regarding Nasdaq listing compliance (minimum $2.5 million requirement).
Outlook, Risks, and Management Commentary
Going Concern and Liquidity
Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. With only $0.73 million in cash and no revenue, the company expects to fund operations only through the fourth quarter of 2025 without additional financing. The company is actively seeking capital through its At-The-Market (ATM) facility and potential strategic transactions.
Strategic Transactions
- SKNY Merger: A shareholder vote is scheduled for September 11, 2025, to approve a stock-for-stock merger with SKNY Pharmaceuticals. SKNY is expected to provide a $5 million capital infusion upon closing.
- Recent Capital Raises: In July 2025 (subsequent to the period end), the company raised approximately $2.0 million via block sales and $0.2 million via ATM sales to address equity deficiencies.
Operational Milestones
- Ketamir-2: Phase 1 clinical trial is ongoing; FDA cleared the Investigational New Drug (IND) application in July 2025. Phase IIa trials for neuropathic pain are anticipated by the end of 2025.
- SKNY-1: New preclinical data in July 2025 showed efficacy in weight loss and reversal of nicotine-seeking behavior.
- MIRA-55: Preclinical results in July 2025 demonstrated morphine-comparable pain relief without local inflammation.
Risks
- Nasdaq Delisting: The company received notice of non-compliance with minimum stockholders' equity requirements. Failure to regain compliance by October 6, 2025, could result in delisting.
- Funding Dependency: Continued operations and clinical trials are entirely dependent on securing external equity or debt financing.
- Related Party Reliance: The company relies on a related party (MIRALOGX) for its primary license and potential funding.
Investor Verification Checklist
- Merger Completion: Verify the outcome of the shareholder vote on the SKNY Pharmaceuticals merger scheduled for September 11, 2025.
- Capital Sufficiency: Confirm whether the recent July 2025 capital raises and the potential SKNY infusion are sufficient to meet the $2.5 million Nasdaq equity requirement by the October 6, 2025 deadline.
- Cash Burn Rate: Monitor the monthly cash burn rate to assess runway beyond Q4 2025.
- Clinical Progress: Track the initiation of Phase IIa trials for Ketamir-2 and the timeline for any regulatory filings.
- Dilution Impact: Review the impact of ongoing ATM offerings and the SKNY stock-for-stock exchange on existing shareholder ownership.